Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Curr Cancer Drug Targets. 2012 Jun;12(5):522-30. doi: 10.2174/156800912800673248.
Acute myeloid leukemia (AML) is a challenging disease to treat with the majority of patients dying from their illness. While overall survival has been markedly prolonged in acute promyelocytic leukemia (APL), survival in younger adults with other subtypes of AML has only modestly improved over the last twenty years. Physicians who treat AML eagerly await drugs like Imatinib for chronic myeloid leukemia, Cladribine for hairy cell leukemia, and Rituximab for non-Hodgkin Lymphoma which have had an important impact on improving outcome. Recent research efforts have focused on refining traditional chemotherapeutic agents to make them more active in AML, targeting specific genetic mutations in myeloid leukemia cells, and utilizing novel agents such as Lenalidomide that have shown activity in other hematologic malignancies. Here, we focus on reviewing the recent literature on agents that may assume a role in clinical practice for patients with AML over the next five years.
急性髓系白血病（AML）是一种难以治疗的疾病，大多数患者死于该病。虽然急性早幼粒细胞白血病（APL）的总体生存率已经显著延长，但在过去二十年中，其他类型 AML 的年轻患者的生存率仅略有改善。治疗 AML 的医生急切地等待像伊马替尼治疗慢性髓性白血病、克拉屈滨治疗毛细胞白血病和利妥昔单抗治疗非霍奇金淋巴瘤这样的药物，这些药物对改善预后产生了重要影响。最近的研究工作集中在改进传统化疗药物，使其在 AML 中更具活性，针对髓性白血病细胞中的特定基因突变，并利用来那度胺等新型药物，这些药物在其他血液恶性肿瘤中显示出活性。在这里，我们重点回顾了最近关于未来五年可能在 AML 患者临床实践中发挥作用的药物的文献。
